Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T18:28:44.075Z.
Calculation as of: 2026-10-06T18:28:44.075Z.
Quote observation: 2026-10-06T18:25:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ca1169366ca7231828fa2f87c24c2e776dca628497ffd55dbb7a20e210c1aea1
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$1.21B
EV/EBIT Ratio
191.82x
TTM Avg
76.16x
3Y Avg
60.11x
5Y Avg
60.11x
Market Cap
$1.22B
EV/EBIT Ratio
19.15x
TTM Avg
131.59x
3Y Avg
131.59x
5Y Avg
72.61x
Market Cap
$1.22B
EV/EBIT Ratio
59.99x
TTM Avg
63.01x
3Y Avg
63.01x
5Y Avg
63.01x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | $1.20B | N/A | N/A | N/A | N/A |
| ORIC Pharmaceuticals, Inc. (ORIC)vs › | $1.20B | N/A | N/A | N/A | N/A |
| MannKind Corporation (MNKD)vs › | $1.21B | 191.82x | 76.16x | 60.11x | 60.11x |
| Innovage Holding Corp. (INNV)vs › | $1.22B | 19.15x | 131.59x | 131.59x | 72.61x |
| Cronos Group Inc. (CRON)vs › | $1.22B | 59.99x | 63.01x | 63.01x | 63.01x |
| Omada Health (OMDA)vs › | $1.23B | N/A | N/A | N/A | N/A |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.17B | N/A | N/A | N/A | N/A |
| Kardigan, Inc. (KARD)vs › | $1.25B | N/A | N/A | N/A | N/A |
| Nektar Therapeutics (NKTR)vs › | $1.14B | N/A | 9.18x | 9.18x | 16.99x |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.14B | 14.07x | 11.45x | 12.41x | 16.01x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
